Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Family Connections Transdiagnostic for Relatives of People With Emotional Dysregulation (FC-T)

22 de maio de 2026 atualizado por: Verónica Guillén-Botella, University of Valencia

Family Connections Transdiagnostic: Study Protocol for a Randomized Controlled Trial Evaluating Efficacy in Relatives of People With Emotional Dysregulation

The aim of this study is to evaluate the efficacy of the Family Connections Transdiagnostic (FC-T) program in relatives of individuals with psychological disorders associated with emotional dysregulation through a randomized controlled trial.

Visão geral do estudo

Descrição detalhada

Emotional dysregulation (ED) is a core transdiagnostic process characterized by heightened emotional sensitivity, intense emotional responses, and difficulties returning to baseline emotional states. It is present across a wide range of psychological disorders, including eating disorders (EDs), Cluster B personality disorders (PD), and disruptive, impulse-control, and conduct disorders. These conditions are associated with significant impairments in social functioning and are often accompanied by psychological symptoms such as depression, anxiety, interpersonal difficulties, and reduced quality of life. In addition, maladaptive strategies to cope with emotional distress (e.g., self-harm, impulsivity, aggression, binge eating) contribute to the maintenance and severity of these disorders.

Families of individuals with psychological disorders characterized by ED experience a high burden of illness and frequently report elevated levels of psychological distress, including anxiety and depression, as well as impairments in their own quality of life. Despite their key role as primary caregivers, family members often lack the necessary skills to effectively manage emotional crises and daily challenges, which may contribute to dysfunctional family dynamics and increased conflict. Although some intervention programs have been developed for caregivers of specific disorders, there is currently a lack of transdiagnostic treatments specifically designed for relatives of individuals with ED.

A skills training program called "Family Connections" (FC) was developed by Hoffman and Fruzzetti's group for relatives of individuals with borderline personality disorder (BPD). It is a program consisting of 12 weekly two-hour sessions delivered in a group format. It is divided into six modules that include psychoeducation about the disorder and its impact on family functioning, as well as skills adapted from Dialectical Behavior Therapy, such as mindfulness, emotion regulation, validation, radical acceptance, and problem management, among others. In addition, all modules include practical exercises, video examples, and homework assignments. Previous studies have shown that this program leads to significant reductions in caregiver burden, perceived distress, depression, and anxiety, as well as improvements in coping strategies and family functioning.

The present study aims to develop and evaluate a transdiagnostic adaptation of the program (Family Connections Transdiagnostic; FC-T), designed to be applied to relatives of individuals with psychological disorders characterized by emotional dysregulation, regardless of specific diagnosis. The psychoeducational modules will be adapted to address ED as a common underlying mechanism, while maintaining the core skills training components of the original program.

The aims of this study are the following: (a) to adapt and test, in the Spanish population, the modules of the FC-T intervention protocol for relatives of patients with psychological disorders characterized by ED; (b) to test the efficacy of FC-T in reducing caregiver burden and clinical symptomatology and improving family relationships and quality of life; (c) to test its efficiency, understood as the acceptance of the intervention program by participants and clinicians, and to demonstrate its feasibility; and (d) to carry out an effective dissemination of this protocol.

This paper presents the study protocol. The study design consists of a two-arm randomized controlled trial with two conditions: Family Connections Transdiagnostic (FC-T) or Treatment as usual optimized (TAU-O). Participants will be family members of patients diagnosed, according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), with eating disorders, Cluster B personality disorders, or disruptive, impulse-control, and conduct disorders. The caregivers' primary outcome measures will be the Burden Assessment Scale (BAS) and a Family-Patient Critical Incident Record. Secondary outcomes will include measures of family functioning, clinical symptomatology, coping strategies, and quality of life. Patient-related outcomes will include measures of emotional dysregulation and impulsivity. Participants will be assessed at pre-treatment, post-treatment, and twelve-month follow-up. The intention-to-treat principle will be used when analyzing data, using mixed-effects models with full information and maximum likelihood estimation.

Tipo de estudo

Intervencional

Inscrição (Estimado)

172

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Valencia
      • Valencia, Valencia, Espanha, 46010
        • University of Valencia

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • • Being 18 years of age or older.

    • Being a family member (e.g., parent, partner, sibling, or other close relative) of a patient diagnosed, according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), with a psychological disorder characterized by emotional dysregulation (e.g., eating disorders, Cluster B personality disorders, or disruptive, impulse-control, and conduct disorders).
    • The patient must currently be receiving treatment in a participating clinical center.
    • Having sufficient knowledge and understanding of the Spanish language to complete the assessments and participate in the intervention.
    • Providing written informed consent to participate in the study.

Exclusion Criteria:

  • • Presence of any severe mental disorder or condition in the family member that may interfere with participation in the intervention (e.g., psychotic disorders, schizophrenia, severe cognitive impairment, or intellectual disability).

    • Current substance dependence that may hinder participation in the study.
    • Severe clinical instability in the patient that prevents the family member from participating in the intervention (as judged by clinicians).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Family Connections Transdiagnostic for relatives of people with emotional dysregulation

- 12 weekly group sessions (2 hours each)

Modules:

  1. Introduction and psychoeducation on ED
  2. Development and explanatory models of ED
  3. Emotional regulation and mindfulness
  4. Acceptance and family environment improvement
  5. Communication and validation
  6. Problem-solving
The intervention lasts 3 months and includes 12 two-hour sessions in a group format on a weekly basis. The FC-T program is divided into 6 modules: 2 modules of psychoeducation on emotional dysregulation (ED) and 4 modules of Dialectical Behavior Therapy (DBT)-based skills training (relationship mindfulness, emotional regulation, acceptance, validation, and problem management).
Comparador Ativo: Optimized Treatment as Usual (TAU-O)
Usual care + psychoeducational session on ED
Family members will receive the usual care available in their clinical setting. In addition, they will participate in a single 3-hour group psychoeducation session including the following components: (1) up-to-date information and research on emotional dysregulation (epidemiology, frequency, comorbidity, risk and protective factors); and (2) psychoeducation on the development of emotional dysregulation, explanatory models, and available treatments.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Record of critical family-patient incidents
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Frequency of problem behaviors in the past 3 months, including suicide attempts, self-harm episodes, visits to psychiatric emergency services, episodes of binge eating, substance use (alcohol or drugs), stealing, fire-setting, verbal aggression, and physical aggression.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Burden Assessment Scale (BAS)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 19-item scale that assesses the caregiver's objective and subjective burden due to the illness of their relative within the past six months using a 4-point Likert scale ranging from 1 (not at all) to 4 (a lot). Higher scores indicate greater caregiver burden. The scale shows adequate validity and reliability, with Cronbach's alpha coefficients ranging from .89 to .91.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Family Assessment Device - Global Functioning Scale (FAD-GF)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 60-item self-report measure of family functioning assessing domains such as communication, roles, affective involvement, and general functioning. Items are rated on a 4-point Likert scale. The instrument shows good internal consistency, with Cronbach's alpha coefficients ranging between .72 and .83 for subscales and around .92 for general functioning.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Depression, Anxiety and Stress Scale (DASS-21)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 21-item scale that measures clinical symptoms such as depression, anxiety, and stress. Items are rated on a 4-point Likert scale ranging from 0 (did not apply to me) to 3 (applied to me most of the time). It shows excellent internal consistency, with Cronbach's alpha coefficients of approximately .94 for depression, .87 for anxiety, and .91 for stress.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Quality of Life Index (QLI)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
This instrument assesses perceived quality of life across several domains, including health, psychological well-being, and social relationships. Higher scores indicate better quality of life. The Spanish version has demonstrated adequate reliability and validity, with good internal consistency indices.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Mastery and Empowerment Scale (MES)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 34-item scale that evaluates coping strategies, perceived control, and empowerment across family, service system, and community domains. Items are rated on a 5-point Likert scale. Previous studies have demonstrated robust psychometric properties, including good internal consistency and construct validity across different samples.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Opinion of Treatment Scale
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
This scale assesses participants' satisfaction, acceptance, and perceived usefulness of the intervention program. It evaluates aspects such as satisfaction, perceived effectiveness, and willingness to recommend the program. Items are rated on a Likert-type scale ranging from 0 to 10. This measure has been adapted from previous treatment opinion scales and shows adequate face validity for assessing treatment acceptability.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Difficulties in Emotion Regulation Scale (DERS) (for Patients)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a self-report measure assessing difficulties in emotion regulation. The Spanish adaptation includes 28 items across five dimensions (lack of emotional control, interference in goal-directed behavior, lack of emotional awareness, emotional confusion, and emotional rejection). Items are rated on a Likert scale from 1 to 5. The scale shows very good internal consistency (Cronbach's alpha ≈ .93) and good test-retest reliability (r ≈ .74).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Barratt Impulsiveness Scale (BIS) (for Patients)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
This instrument assesses impulsivity as a multidimensional construct, including attentional, motor, and non-planning impulsivity. Items are rated on a Likert-type scale. The Spanish adaptation has demonstrated adequate psychometric properties, including good internal consistency and construct validity.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Family Assessment Device - Global Functioning Scale (FAD-GF) (for Patients)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a self-report measure of family functioning assessing domains such as communication, roles, affective involvement, and general functioning. It shows good internal consistency, with Cronbach's alpha coefficients ranging from .72 to .83 and up to .92 for general functioning.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Validating and Invalidating Responses Scale (VIRS) (for Patients)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 16-item scale that assesses perceived validation and invalidation in caregiver responses. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (almost always). The scale has shown adequate internal consistency and construct validity in previous studies.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Lum Emotional Availability of Parents (LEAP) (for Patients)
Prazo: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 15-item questionnaire that assesses perceived emotional availability of caregivers. Items are rated on a 6-point Likert scale. The instrument shows excellent internal consistency (Cronbach's alpha ≈ .92 for mothers and .93 for fathers) and good test-retest reliability (r ≈ .92 and r ≈ .85, respectively).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Cadeira de estudo: Laura Díaz-Sanahuja, Dr. Professor, University of Valencia
  • Cadeira de estudo: Cayetana Garoz, PhD, University of Castellón
  • Cadeira de estudo: Álvaro Cadiñanos, PhD, University of Valencia
  • Cadeira de estudo: Elena González-Perpiñá, PhD, University of Valencia
  • Cadeira de estudo: Antonio Arnal, PhD, University of Valencia
  • Cadeira de estudo: Ginnette Muñoz, PhD, University of Valencia

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de maio de 2026

Conclusão Primária (Estimado)

25 de dezembro de 2026

Conclusão do estudo (Estimado)

25 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

6 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de maio de 2026

Primeira postagem (Real)

14 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Individual participant data will be available after de-identification.

Prazo de Compartilhamento de IPD

The data will be available immediately after publication

Critérios de acesso de compartilhamento IPD

The data will be available to anyone who wishes and justify to access them

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever